Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

New Drug Update for The Week Ending May 18

5/21/2019

 
Regulatory Update

The FDA informed ImmunoGen that it would not accept sub-group data from patients with high levels of folate receptor alpha enrolled in the failed FORWARD I trial evaluating mirvetuximab soravtansine for NDA approval. ImmunoGen will need to run a new Phase III trial in patients with high folate receptor alpha expression, platinum-resistant ovarian cancer before seeking approval.

An FDA review of quizartinib questioned the credibility of some clinical trial data due to inconsistencies, lack of efficacy for secondary endpoints and imbalances between the study arms. The FDA’s Oncology Drug Advisory Committee voted 3 to 8 against recommending approval of quizartinib for the treatment of relapsed or refractory acute myeloid leukemia in May 2019.

An FDA review of
pexidartinib expressed concern about data lacking for physical function, stiffness and range of motion and changes in the statistical analysis plan. The FDA’s Oncology Drug Advisory Committee voted 12 to 3 to recommending approval of pexidartinib for the treatment of giant cell tumor of the tendon sheath May 2019

The FDA’s Allergenic Products Advisory Committee will review Aimmune Therapeutics’ AR101
on 9/13/2019.  AR101 is an oral immunotherapy used to desensitize the patient to Peanut allergy.

The FDA has put a partial hold on an axalimogene filolisbac Phase III cervical cancer trial in January 2019, until Advaxis provided additional chemistry, manufacturing and controls information. Under the hold, no new patients could be enrolled in the trial, but current patients can continue to be treated. The FDA lifted the partial band on the cervical cancer trial on 5/15/2019.

Announced Research Updates

Myovant announced that in the 24-week, 388 patient, Phase III, LIBERTY trial, 73.4% of patients treated with relugolix, estradiol and norethindrone acetate achieved a menstrual blood loss volume of less than 80 mL and a 50 percent or greater reduction from baseline in menstrual blood loss volume during the last 35 days of the 24-week treatment period compared to 18.9% with placebo in patients with uterine fibroids and heavy menstrual bleeding.

UniQure announced interim data from a 52-week, 3 patient, Phase IIb trial, where after 6-months treatment with a single infusion of AMT-061 had a mean increase in Factor IX (FIX) activity of 47% (individual results: 33%, 51%, 57%) and no patient required a Factor IX infusion, experienced a bleeding event or required immunosuppression.

The Medicines Company announced that in Orion-3, a 3-year extension study of ORION-1, inclisiran lowered LDL at least 50% at all doses and frequency.

Published Research Updates

The 20-month, 572 patient, Phase III SOLAR-1 trial enrolled a population of men and postmenopausal women with HR+/HER2- advanced breast cancer whose cancer progressed after at least 12 months of an aromatase inhibitor therapy. In a subset of 341 who harbored PIK3CA mutations, PFS was 11 months with alpelisib/fulvestrant and 5.7 months with fulvestrant monotherapy. In the subset whowithout PIK3CA-mutated cancer, the overall response rate was 26.6% with alpelisib/fulvestrant compared to 12.8% with fulvestrant monotherapy. 

In a 28-day, 256 patient, Phase III trial, brimapitide did not improve hearing loss compared to placebo in patients with unilateral idiopathic sudden sensorineural hearing loss (ISSNHL). A post-hoc analysis found a benefit in patients with profound ISSNHL.

In a 187 patient, Phase I, open-label trial, treatment with erdafitinib resulted in a 46.2% overall response rate (ORR) in patients with urothelial carcinoma and a 27.3% ORR in patients with cholangiocarcinoma in patients with treatment resistant, pan-fibroblast growth factor receptor (FGFR) positive tumors. The ORR for all other tumor types of < 10%.

In a 560-patient trial, 31.4% of patients treated with amisulpride had no emesis or need of rescue medications compared to 21.5% with placebo in patients at low-to-moderate risk for PONV who had not received any prior prophylaxis.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.